Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBT NASDAQ:CMND NASDAQ:EVFM NASDAQ:XBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$2.19-2.7%$2.64$1.87▼$11.66$4.26M-0.021.45 million shs35,931 shsCMNDClearmind Medicine$1.02$0.97$0.80▼$2.18$4.35M0.96312,159 shs49,600 shsEVFMEvofem Biosciences$0.01+4.3%$0.01$0.01▼$0.02$1.15M-0.99409,856 shs1.96 million shsXBIOXenetic Biosciences$2.92-2.3%$3.37$2.20▼$5.27$4.61M2.3147,840 shs9,209 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare-2.67%-7.20%-15.77%-41.13%-69.47%CMNDClearmind Medicine0.00%0.00%+4.94%+3.03%-8.93%EVFMEvofem Biosciences+4.30%+5.43%+4.30%+5.43%-3.00%XBIOXenetic Biosciences-2.34%-1.68%-21.93%+0.34%-11.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALBTAvalon GloboCare1.1754 of 5 stars0.02.00.04.32.41.70.0CMNDClearmind Medicine1.0222 of 5 stars0.04.00.00.02.91.70.0EVFMEvofem Biosciences1.7636 of 5 stars0.05.00.04.82.50.00.0XBIOXenetic Biosciences0.7355 of 5 stars0.03.00.00.02.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBTAvalon GloboCare 0.00N/AN/AN/ACMNDClearmind Medicine 0.00N/AN/AN/AEVFMEvofem Biosciences 0.00N/AN/AN/AXBIOXenetic Biosciences 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBTAvalon GloboCare$1.33M3.11N/AN/A($11.37) per share-0.19CMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/AEVFMEvofem Biosciences$11.39M0.10N/AN/A($2.64) per share0.00XBIOXenetic Biosciences$2.50M1.80N/AN/A$2.88 per share1.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBTAvalon GloboCare-$7.90M-$19.96N/A∞N/A-647.29%N/A-50.13%8/18/2025 (Estimated)CMNDClearmind Medicine-$5.26M-$1.10N/A∞N/AN/A-164.79%-71.12%9/15/2025 (Estimated)EVFMEvofem Biosciences$52.98M-$0.05N/A∞N/A-46.42%-91.97%-61.93%N/AXBIOXenetic Biosciences-$3.96M-$2.38N/AN/AN/A-126.08%-54.56%-47.28%N/ALatest EVFM, XBIO, CMND, and ALBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ALBTAvalon GloboCareN/A-$2.02N/A-$6.22N/AN/A8/12/2025Q2 2025XBIOXenetic Biosciences-$0.64-$0.45+$0.19-$0.45$0.48 million$0.59 million6/12/2025Q2 2025CMNDClearmind MedicineN/A-$0.16N/A-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBTAvalon GloboCareN/AN/AN/AN/AN/ACMNDClearmind MedicineN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBTAvalon GloboCareN/A0.190.19CMNDClearmind MedicineN/A1.741.74EVFMEvofem BiosciencesN/A0.110.09XBIOXenetic BiosciencesN/A5.938.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBTAvalon GloboCare1.42%CMNDClearmind Medicine96.05%EVFMEvofem Biosciences0.22%XBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipALBTAvalon GloboCare37.30%CMNDClearmind MedicineN/AEVFMEvofem Biosciences0.01%XBIOXenetic Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBTAvalon GloboCare51.89 million1.19 millionNot OptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableXBIOXenetic Biosciences41.54 million1.32 millionNot OptionableEVFM, XBIO, CMND, and ALBT HeadlinesRecent News About These CompaniesXenetic Biosciences, Inc. Reports Second Quarter 2025 Financial ResultsAugust 13 at 8:00 AM | accessnewswire.comAXenetic Biosciences Reports Improved Financial PerformanceAugust 13 at 3:40 AM | msn.comXenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue EstimatesAugust 12 at 7:26 PM | zacks.comXenetic Biosciences (XBIO) to Release Earnings on TuesdayAugust 10, 2025 | americanbankingnews.comXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell LymphomaJuly 30, 2025 | accessnewswire.comAXenetic Biosciences expands R&D collaboration with The Scripps Research Institute to advance DNase platformJuly 26, 2025 | pharmabiz.comPXenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformJuly 23, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the ...July 8, 2025 | finanznachrichten.deXenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic CancerJuly 8, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | accessnewswire.comAXenetic Biosciences (XBIO) Receives a Hold from H.C. WainwrightApril 9, 2025 | markets.businessinsider.comXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentApril 9, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentApril 9, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing SarcomaMarch 26, 2025 | accessnewswire.comAXenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 20, 2025 | finance.yahoo.comXenetic Biosciences, Inc. Reports Full Year 2024 Financial ResultsMarch 19, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic ResponsesMarch 13, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy MeetingFebruary 27, 2025 | accessnewswire.comAXenetic Biosciences extends research agreement with University of Virginia for the advancement of its DNase-based oncology platformDecember 18, 2024 | pharmabiz.comPXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentDecember 17, 2024 | accesswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVFM, XBIO, CMND, and ALBT Company DescriptionsAvalon GloboCare NASDAQ:ALBT$2.19 -0.06 (-2.67%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$2.24 +0.05 (+2.28%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Clearmind Medicine NASDAQ:CMND$1.02 0.00 (0.00%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.01 -0.01 (-0.49%) As of 08/14/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Evofem Biosciences NASDAQ:EVFM$0.0097 +0.00 (+4.30%) As of 08/14/2025 03:59 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Xenetic Biosciences NASDAQ:XBIO$2.92 -0.07 (-2.34%) Closing price 08/14/2025 03:55 PM EasternExtended Trading$2.83 -0.09 (-3.08%) As of 08/14/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Deere’s Sell-Off Could Be a Long-Term Buying Chance Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go? Mercury Systems Up 27%: Financials Send Investors a Clear Signal Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access